Lipid nanoparticles (LNPs) have emerged as one of the most transformative drug delivery technologies in modern medicine. Their success in enabling mRNA vaccines has accelerated investment across gene therapy, RNA therapeutics, oncology, rare diseases, and personalized medicine. As pharmaceutical and biotechnology companies race to develop next-generation nucleic acid therapies, LNP technology has become a critical component of the global biopharmaceutical ecosystem.
The global lipid nanoparticles market, valued at US$261.8 million in 2023, stood at US$271.8 million in 2024 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2029, culminating in a forecasted valuation of US$350.5 million by the end of the period. The global lipid nanoparticles services market is projected to reach USD 238.1 million by 2029 from USD 135.5 million in 2024, at a CAGR of 11.9% during the forecast period.
The growing demand for mRNA vaccines, siRNA therapeutics, CRISPR-based gene editing, and targeted drug delivery systems is driving rapid expansion of the lipid nanoparticles market. Companies are investing heavily in proprietary lipid formulations, scalable manufacturing platforms, advanced encapsulation technologies, and contract development and manufacturing (CDMO) capabilities to support the commercialization of RNA-based medicines.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=70136984
Top 20 Companies in the Lipid Nanoparticles Market
1. Merck KGaA
A leading supplier of pharmaceutical-grade lipids, RNA manufacturing solutions, and CDMO services, Merck has strengthened its LNP capabilities through strategic acquisitions and investments in RNA therapeutics manufacturing.
2. Evonik Industries AG
Evonik is a major producer of GMP-grade lipids and offers end-to-end LNP formulation and manufacturing services for mRNA and gene therapy applications.
3. Acuitas Therapeutics
Widely recognized for its proprietary LNP delivery technologies, Acuitas has played a crucial role in advancing several clinically validated mRNA therapeutics and vaccines.
4. Danaher Corporation (Precision NanoSystems)
Through Precision NanoSystems, Danaher provides industry-leading microfluidic platforms for scalable and reproducible LNP manufacturing.
5. Croda International plc (Avanti Polar Lipids)
Avanti Polar Lipids is among the world’s leading suppliers of high-purity lipids used in pharmaceutical research and LNP formulation.
6. Moderna
The company’s mRNA platform relies heavily on advanced LNP technology, making it one of the most influential innovators in the market.
7. Pfizer
Pfizer’s success with mRNA vaccine commercialization has positioned the company as a major user and developer of LNP-enabled therapeutics.
8. BioNTech
BioNTech continues to advance LNP-enabled cancer immunotherapies, vaccines, and personalized medicine solutions.
9. CordenPharma
A leading CDMO specializing in lipid chemistry, CordenPharma offers comprehensive LNP development and manufacturing services.
10. Lonza
Lonza provides integrated mRNA and LNP manufacturing services supporting clinical and commercial-scale production.
11. Arcturus Therapeutics
Known for its proprietary LUNAR® delivery platform, Arcturus is advancing mRNA vaccines and RNA therapeutics.
12. Genevant Sciences
Genevant develops next-generation ionizable lipids and delivery systems for RNA medicines and gene-editing applications.
13. NOF Corporation
The Japanese specialty chemical company is a leading provider of lipid excipients and ionizable lipids used in LNP formulations.
14. Nippon Fine Chemical
The company supplies specialized lipid materials and supports pharmaceutical manufacturers developing advanced drug delivery systems.
15. Lipoid GmbH
Lipoid is a global supplier of phospholipids and lipid excipients utilized in pharmaceutical and biotechnology applications.
16. FUJIFILM Pharmaceutical / Fujifilm Diosynth Biotechnologies
Fujifilm continues to expand its biopharmaceutical manufacturing capabilities, including support for nucleic acid therapies.
17. Creative Biolabs
The company offers research, formulation development, and analytical services for lipid nanoparticle applications.
18. BIOVECTRA
BIOVECTRA has become a strategic manufacturing partner for lipid production and mRNA therapeutic supply chains.
19. Ascendia Pharmaceuticals
Ascendia focuses on innovative drug delivery technologies and advanced nanoparticle formulation development.
20. Thermo Fisher Scientific
Thermo Fisher supports the LNP ecosystem through analytical tools, manufacturing technologies, and bioprocessing solutions.
Future Outlook
The lipid nanoparticles market is expected to witness significant growth as RNA therapeutics move from research laboratories into commercial healthcare applications. Advances in targeted delivery, tissue-specific LNPs, improved safety profiles, and scalable manufacturing technologies will continue to shape the competitive landscape. Companies that successfully integrate proprietary lipid chemistry, manufacturing expertise, and strategic partnerships will be best positioned to capitalize on the next wave of innovation in gene therapy, mRNA vaccines, and precision medicine.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=70136984